Bank of New York Mellon’s Transmedics TMDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.9M Sell
193,752
-17,616
-8% -$1.49M ﹤0.01% 1901
2026
Q1
$21M Sell
211,368
-7,228
-3% -$943K ﹤0.01% 1514
2025
Q4
$26.6M Buy
218,596
+6,799
+3% +$853K ﹤0.01% 1377
2025
Q3
$23.8M Sell
211,797
-9,479
-4% -$1.11M ﹤0.01% 1453
2025
Q2
$29.7M Buy
221,276
+11,599
+6% +$1.27M 0.01% 1301
2025
Q1
$14.1M Sell
209,677
-143,585
-41% -$9.88M ﹤0.01% 1682
2024
Q4
$22M Sell
353,262
-131,656
-27% -$12.3M ﹤0.01% 1510
2024
Q3
$76.1M Buy
484,918
+64,191
+15% +$9.89M 0.01% 779
2024
Q2
$63.4M Sell
420,727
-111,168
-21% -$13.3M 0.01% 887
2024
Q1
$39.3M Sell
531,895
-155,130
-23% -$12.8M 0.01% 1183
2023
Q4
$54.2M Sell
687,025
-73,074
-10% -$4.41M 0.01% 990
2023
Q3
$41.6M Buy
760,099
+363,012
+91% +$26.1M 0.01% 1110
2023
Q2
$33.3M Sell
397,087
-20,693
-5% -$1.58M 0.01% 1250
2023
Q1
$31.6M Sell
417,780
-49,761
-11% -$3.44M 0.01% 1292
2022
Q4
$28.9M Sell
467,541
-171,143
-27% -$9.1M 0.01% 1339
2022
Q3
$26.7M Sell
638,684
-44,437
-7% -$1.93M 0.01% 1328
2022
Q2
$21.5M Buy
683,121
+93,299
+16% +$2.49M ﹤0.01% 1495
2022
Q1
$15.9M Sell
589,822
-46,069
-7% -$825K ﹤0.01% 1809
2021
Q4
$12.2M Buy
635,891
+535,782
+535% +$13.4M ﹤0.01% 1994
2021
Q3
$3.31M Buy
100,109
+24,827
+33% +$759K ﹤0.01% 2712
2021
Q2
$2.5M Sell
75,282
-131,131
-64% -$3.63M ﹤0.01% 2854
2021
Q1
$8.56M Buy
206,413
+3,616
+2% +$111K ﹤0.01% 2177
2020
Q4
$4.04M Sell
202,797
-5,185
-2% -$76.7K ﹤0.01% 2457
2020
Q3
$2.87M Buy
207,982
+130,904
+170% +$2.24M ﹤0.01% 2478
2020
Q2
$1.38M Buy
77,078
+21,927
+40% +$343K ﹤0.01% 2912
2020
Q1
$666K Buy
55,151
+17,927
+48% +$300K ﹤0.01% 3230
2019
Q4
$708K Buy
37,224
+13,965
+60% +$256K ﹤0.01% 3402
2019
Q3
$552K Buy
23,259
+10,076
+76% +$242K ﹤0.01% 3479
2019
Q2
$382K Buy
+13,183
New +$360K ﹤0.01% 3726

Other funds holding TMDX

Bank of New York Mellon's TMDX Position: Q2 2026 in Review

Bank of New York Mellon reduced its Transmedics (TMDX) stake by 8.3% in Q2 2026, selling an estimated $1.49M and leaving 193,752 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1901.

Bank of New York Mellon first reported a position in TMDX in Q2 2019 and has held it in 29 quarters since. The position peaked at $76.1M in Q3 2024. 234 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

  • Bank of New York Mellon held 193,752 shares of Transmedics worth $12.9M as of Q2 2026.
  • Bank of New York Mellon sold 17,616 Transmedics shares in Q2 2026, an estimated $1.49M.
  • Transmedics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1901 holding.
  • Bank of New York Mellon first reported a position in Transmedics in Q2 2019 and has held it in 29 quarters since.
  • Bank of New York Mellon's Transmedics position peaked at $76.1M in Q3 2024.
  • 234 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.